The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMedium•31 March 2026•

1 min read

Haemonetics Secures FDA Label Expansion for VASCADE MVP XL System

Key Facts

1Haemonetics received FDA approval to expand the labeling for its VASCADE MVP XL venous vascular closure system.

2The expansion allows the system to be used with larger procedural sheaths in advanced electrophysiology procedures.

3The approval is supported by clinical trial data, strengthening the company's position in the electrophysiology market.

Create Free Account

Haemonetics Corporation (HAE) has received approval from the U.S. Food and Drug Administration (FDA) to expand the labeling for its VASCADE MVP XL venous vascular closure system. This regulatory milestone allows the system to be utilized with larger procedural sheaths, specifically targeting advanced electrophysiology procedures. The expansion is backed by robust clinical trial data, which underscores the safety and efficacy of the device in complex cardiac cases. By broadening the clinical application of VASCADE MVP XL, Haemonetics aims to solidify its competitive position within the high-growth electrophysiology market. This development is expected to drive commercial growth as the company leverages its enhanced product utility to meet evolving surgical needs. Furthermore, the approval reflects the company's commitment to innovation and its ability to navigate rigorous regulatory environments to expand its market reach.